Table 1.

Baseline characteristics of the patients

Rosuvastatin (n = 388)Placebo (n = 343)
Female gender, n (%)135 (35)117 (34)
Mean (SD) age, yr65 (8.2)65 (8.5)
Caucasian, n (%)295 (76)257 (75)
Mean (SD) body mass index, kg/m226.6 (5.0)26.9 (5.7)
Mean (SD) blood pressure, mmHg
    Systolic140.3 (23.9)141.3 (26.6)
     Diastolic75.6 (11.7)74.4 (13.2)
Mean (SD)
    Calcium, mmol/L2.3 (0.2)2.3 (0.2)
    Phosphate, mmol/L1.8 (0.6)1.8 (0.5)
    Albumin, g/L39.3 (3.5)39.3 (3.6)
    Hemoglobin, g/dl11.6 (1.6)11.4 (1.7)
Current smoker, n (%)34 (9)54 (16)
Mean (SD) years on hemodialysis2.4 (2.0)2.4 (2.1)
History of cardiovascular disease, n (%)218 (56)192 (56)
    peripheral artery disease100 (26)94 (27)
    chronic angina105 (27)82 (24)
    myocardial infarction62 (16)42 (12)
    ischemic cerebral vascular accident55 (14)38 (11)
    coronary revascularization35 (9)28 (8)
    carotid artery disease28 (7)23 (7)
    transient ischemic attack24 (6)19 (6)
Baseline medication, n (%)
    ACE/ARB169 (44)153 (45)
    Beta-blocker150 (37)105 (39)
Mean (SD) Lipid levels, mmol/l
    total cholesterola4.49 (1.15)4.35 (1.09)
    LDL-Cb2.51 (0.89)2.43 (0.87)
    HDL-Cc1.11 (0.38)1.08 (0.38)
    triglycerided1.90 (1.29)1.85 (1.13)
Median (interquartile range) hsCRP, mg/L5.02 (1.91–14.25)5.51 (1.99–15.18)
  • aTo convert to mg/dl, divide by 0.02586.

  • bTo convert to mg/dl, divide by 0.02586.

  • cTo convert to mg/dl, divide by 0.02586.

  • dTo convert to mg/dl, divide by 0.01129.

  • ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.